As a model compound we selected galantamine that is marketed as an AD drug and has been described in the literature as a drug with the desired dual mode of action, i.e., inhibitor of the AChE and a PAM at the α7 nAChRs [18,19]. This evidence concerns the gene ACHE and Alzheimer disease.